DNB Bioteknologi is an actively managed global equity fund with a track record back to 2020. The management company is DNB Asset Management in Oslo, the fund arm of DNB, Norway's largest bank. The company is indirectly wholly owned by DNB Bank ASA.
Investment philosophy
The mandate is broader than pure biotechnology companies. The fund may invest in biotechnology, diagnostics, pharma, biological drugs including gene therapy and other health-related businesses. It may also invest in companies where only part of the business is tied to health.
The managers
Benedicte Kilander Bakke is the lead manager. She and Rune Sand-Holm have managed the fund since May 2020. Bakke trained as a dentist, holds an MBA from NHH, has a background in the pharmaceutical industry and became a portfolio manager at DNB in 2018. Sand-Holm has a background as an analyst covering shipping, real estate and construction. Anesa Mulabecirovic Sahnoun became a manager in May 2026, after being an analyst on the fund since June 2021. She holds a doctorate in medicine and has worked as a physician and as an investment analyst at Hadean Ventures. The managers are based in Oslo and are part of DNB Asset Management's health care team, which also manages DNB Health Care, where Sand-Holm is lead manager, and DNB Fund Women's Health, launched in August 2026 with Mulabecirovic Sahnoun as lead manager.
The portfolio
The portfolio holds a limited number of companies, and a large share of it sits in large companies. Steady top positions include Argenx, UCB, BioMarin Pharmaceutical, Neurocrine Biosciences and Axsome Therapeutics. The US is the persistent largest country, but European companies such as Argenx and UCB also recur.
FundTelligence description · 24/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.
2 of 4 funds ranked on a calculated return
#4/ 4Year to date
+2.24% NOK
as of 13 Nov 2026 · NOK class
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#4/ 41 year
+10.75% NOK
as of 13 Nov 2026 · NOK class
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#4/ 43 years (ann.)
+10.83% NOK
as of 13 Nov 2026 · NOK class
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#4/ 45 years (ann.)
+7.77% NOK
as of 13 Nov 2026 · NOK class
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
1 year
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.